Comparative effectiveness of long-acting risperidone in New Zealand: A report of resource utilization and costs in a 12-month mirror-image analysis

Clinical Drug Investigation

Volumn 30, Issue 11, 2010, Pages 777-787

  Carswell, Christopher ^a,b   Wheeler, Amanda ^b,c   Vanderpyl, Jane ^d   Robinson, Elizabeth ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^d Te Pou   (New Zealand)

Author keywords

antipsychotics; cost effectiveness; risperidone; schizophrenia; therapeutic use; treatment

Indexed keywords

CLOZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BIPOLAR DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITAL ADMISSION; HOSPITAL BED; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEW ZEALAND; OUTCOME ASSESSMENT; PATIENT INFORMATION; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG COSTS; FEMALE; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMIC; NEW ZEALAND; PATIENT ADMISSION; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956475205     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11537680-000000000-00000     Document Type: Article

References (28)

1. Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008; 26: 149-62
2. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27: 263-72
3. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-91
4. Davis JM, ChenN,Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64
5. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41
6. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability: are patients better off? Can J Psychiatry 2004; 49: 297-302
7. Naber D, Karow A. Good tolerability equals good results: the patients perspective. Eur Neuropsychopharmacol 2001; 11 Suppl. 4: S391-6
8. Hofer A, Kemmler G, Eder U, et al. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002; 63: 49-53
9. Freudenreich O, Cather C, Evins AE, et al. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004; 65: 1372-6
10. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87
11. Hogan G, Sandamas G. A question of choice. London: National Schizophrenia Fellowship, 2000
12. Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients perspective. Aust N Z J Psychiatry 2002; 36: 633-41
13. Zhu B, Ascher-Svanum H, Shi L, et al. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 2008; 59: 315-7
14. Freemantle N, Hessel F. The applicability and generalizability of findings from clinical trials for health-policy decisions. Pharmacoeconomics 2009; 27: 5-10
15. Pharmaceutical Management Agency (PHARMAC). New Zealand pharmaceutical schedule - August 2009. Wellington: PHARMAC, New Zealand Government [online]. Available from URL: http://www.pharmac.govt.nz/2009/08/05/Sched.pdf [Accessed 2009 Sep 22]
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
17. Bailey D. A users guide to the Mental Health (Compulsory Assessment and Treatment) Act. Wellington: Department of Health, 1992
18. New Zealand Health Information Service (NZHIS). Weighted inlier equivalent separations [online]. Available from URL: http://www.nzhis.govt.nz/ moh.nsf/pagesns/300 [Accessed 2009 Aug 6]
19. Organisation for Co-operation and Economic Development (OECD). Purchasing Power Parity and Exchange Rates 2009 [online]. Available from URL: http://stats.oecd.org/Index.aspx?datasetcode=SNA-TABLE4 [Accessed 2009 Aug 6]
20. Personal Social Services Research Unit. Unit costs of health and social care 2008 [online]. Available from URL: http:// www.pssru.ac.uk/pdf/uc/uc2008/ uc2008-s02.pdf [Accessed 2009 Aug 6]
21. Pharmaceutical Management Agency (PHARMAC). Prescription for pharmacoeconomic analysis [online]. Available from URL: http://www.pharmac.govt. nz/2007/06/19/PFPAFinal.pdf [Accessed 2009 Sep 23]
22. Tunis SL. A cost-effectiveness analysis to illustrate the impact of cost definitions on results, interpretations and comparability of pharmacoeconomic studies in the US. Pharmacoeconomics 2009; 27: 735-44
23. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; Suppl.: 18-21
24. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996; 57: 337-45
25. Gurovich I, Kobina S, Lyubov E, et al. Pharmacoeconomic analyses of depot neuroleptic treatment in natural setting [abstract]. Value Health 2000; 3: 79
26. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care.Acta Psych Scand 2007; 116: 36-46
27. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006; 114: 14-20
28. Taylor D, Fischetti C, Sparshatt A, et al. Risperidone longacting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 2009; 120: 97-101